Literature DB >> 15261556

Mechanisms of mitoxantrone in multiple sclerosis--what is known?

Oliver Neuhaus1, Bernd C Kieseier, Hans-Peter Hartung.   

Abstract

The recent publication of the MIMS-study (Mitoxantrone In Multiple Sclerosis) and the approval of several health authorities support the use of mitoxantrone in patients with active relapsing-remitting or secondary progressive multiple sclerosis. This review provides information on data thus far present on the putative mechanisms of action of mitoxantrone in the immunopathogenesis of this disabling disease. Copyright 2004 Elsevier B.V.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15261556     DOI： 10.1016/j.jns.2004.04.015

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Combination therapies in multiple sclerosis.

Authors:  Ralf Gold
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

Review 2.  Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier; Bernhard Hemmer
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

3.  Current and future treatment approaches for neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

4.  Chemobrain: mitoxantrone-induced oxidative stress, apoptotic and autophagic neuronal death in adult CD-1 mice.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Ana Reis-Mendes; Rita Ferreira; Maria Lourdes Bastos; Eduarda Fernandes; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2022-03-19       Impact factor: 6.168

5.  Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis.

Authors:  Samuel A Burns; R Lee Archer; Janet A Chavis; Cameron A Tull; Lori L Hensley; Paul D Drew
Journal:  Brain Res       Date:  2012-08-02       Impact factor: 3.252

Review 6.  Developing therapeutics for the treatment of multiple sclerosis.

Authors:  David J Virley
Journal:  NeuroRx       Date:  2005-10

7.  Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.

Authors:  Vinzenz Fleischer; Anke Salmen; Susanne Kollar; Veronika Weyer; Volker Siffrin; Andrew Chan; Frauke Zipp; Felix Luessi
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

Review 8.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

Review 9.  Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.

Authors:  Madeline Bross; Melody Hackett; Evanthia Bernitsas
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

10.  Inhibiting AKT phosphorylation employing non-cytotoxic anthraquinones ameliorates TH2 mediated allergic airways disease and rhinovirus exacerbation.

Authors:  Caio Cesar de Souza Alves; Adam Collison; Luke Hatchwell; Maximilian Plank; Matthew Morten; Paul S Foster; Sebastian L Johnston; Cristiane França da Costa; Mauro Vieira de Almeida; Henrique Couto Teixeira; Ana Paula Ferreira; Joerg Mattes
Journal:  PLoS One       Date:  2013-11-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.